OncoArendi Therapeutics SA (MOC) Ratios
OncoArendi Therapeutics SA Ratios
PL:MOC's free cash flow for Q3 2026 was $0.00. For the 2026 fiscal year, PL:MOC's free cash flow was increased by $8.53M and operating cash flow was $-8.53M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.79 | 9.82 | 10.87 | 10.74 | 18.81 |
| Quick Ratio | 4.79 | 9.82 | 10.87 | 10.74 | 18.81 |
| Cash Ratio | 4.54 | 3.55 | 10.59 | 9.40 | 16.55 |
| Solvency Ratio | -1.81 | -2.66 | -2.25 | -0.82 | -1.28 |
| Operating Cash Flow Ratio | -5.40 | -11.14 | -3.85 | -1.46 | -2.19 |
| Short-Term Operating Cash Flow Coverage | -9.58 | -26.12 | -10.76 | -4.63 | -7.46 |
| Net Current Asset Value | $ 10.24M | $ 39.94M | $ 54.37M | $ 63.38M | $ 105.49M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 0.06 | 0.06 | 0.05 | 0.04 |
| Debt-to-Equity Ratio | 0.06 | 0.07 | 0.07 | 0.05 | 0.04 |
| Debt-to-Capital Ratio | 0.06 | 0.07 | 0.07 | 0.05 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.08 | 1.10 | 1.11 | 1.09 | 1.07 |
| Debt Service Coverage Ratio | -9.05 | -12.02 | -11.32 | -13.56 | -7.34 |
| Interest Coverage Ratio | -286.48 | -356.66 | -360.18 | -2684.38 | -2123.46 |
| Debt to Market Cap | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.26 | 0.36 | 0.43 | 0.46 | 0.43 |
| Net Debt to EBITDA | 0.58 | 0.40 | 2.23 | 1.86 | 7.20 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | -16.78% | -4101610.00% | -0.28% | -693272.50% |
| EBIT Margin | 0.00% | -1068.61% | -28373116.00% | -476.92% | -3407520.50% |
| EBITDA Margin | 0.00% | -937.75% | -25505806.00% | -423.89% | -3332504.75% |
| Operating Profit Margin | 0.00% | -1151.35% | -32128045.00% | -584.40% | -3441074.75% |
| Pretax Profit Margin | 0.00% | -1071.83% | -28373117.00% | -478.49% | -3409079.75% |
| Net Profit Margin | 0.00% | -1071.83% | -28373117.00% | -180.21% | -3410639.00% |
| Continuous Operations Profit Margin | 0.00% | -1071.83% | -28373117.00% | -478.49% | -3409079.75% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 37.66% | 100.05% |
| EBT Per EBIT | 71.20% | 93.09% | 88.31% | 81.88% | 99.07% |
| Return on Assets (ROA) | -16.61% | -27.51% | -25.27% | -9.81% | -9.00% |
| Return on Equity (ROE) | -17.94% | -30.26% | -28.11% | -10.71% | -9.67% |
| Return on Capital Employed (ROCE) | -24.26% | -30.95% | -30.24% | -33.50% | -9.46% |
| Return on Invested Capital (ROIC) | -23.73% | -29.75% | -29.06% | -30.85% | -9.23% |
| Return on Tangible Assets | -65.71% | -52.37% | -37.18% | -15.63% | -10.83% |
| Earnings Yield | -11.62% | -15.33% | -8.64% | -6.77% | -2.61% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.10 | 0.01 | 488.33 | 0.00 |
| Payables Turnover | 0.00 | 1.86 | 1.36 | 0.58 | 1.40 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.31 | 0.00 | 0.65 | 0.00 |
| Asset Turnover | 0.00 | 0.03 | 0.00 | 0.05 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.06 | 0.00 | 0.08 | 0.00 |
| Cash Conversion Cycle | 0.00 | 3594.89 | 34906.60 | -629.59 | 12268699.97 |
| Days of Sales Outstanding | 0.00 | 3790.69 | 35175.05 | 0.75 | 12268961.26 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 195.81 | 268.45 | 630.34 | 261.30 |
| Operating Cycle | 0.00 | 3790.69 | 35175.05 | 0.75 | 12268961.26 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.95 | -2.82 | -1.38 | -0.73 | -0.97 |
| Free Cash Flow Per Share | -0.95 | -4.00 | -1.40 | -3.13 | -2.32 |
| Dividend Paid and CapEx Coverage Ratio | -6471211.00 | -2.40 | -64.30 | -0.30 | -0.72 |
| Capital Expenditure Coverage Ratio | -6471211.00 | -2.40 | -64.30 | -0.30 | -0.72 |
| Operating Cash Flow Coverage Ratio | -3.67 | -7.88 | -3.26 | -1.59 | -2.25 |
| Operating Cash Flow to Sales Ratio | 0.00 | -19.52 | -232900.40 | -1.36 | -33741.04 |
| Free Cash Flow Yield | -14.38% | -39.58% | -7.20% | -21.91% | -6.20% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.57 | -6.52 | -11.57 | -14.78 | -38.25 |
| Price-to-Sales (P/S) Ratio | 0.00 | 69.90 | 3283020.00 | 26.63 | 1304471.96 |
| Price-to-Book (P/B) Ratio | 1.54 | 1.97 | 3.25 | 1.58 | 3.70 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.95 | -2.53 | -13.88 | -4.56 | -16.14 |
| Price-to-Operating Cash Flow Ratio | -6.95 | -3.58 | -14.10 | -19.59 | -38.66 |
| Price-to-Earnings Growth (PEG) Ratio | 0.17 | 0.79 | 0.34 | -0.09 | 0.32 |
| Enterprise Value Multiple | -6.52 | -7.05 | -10.64 | -4.42 | -31.94 |
| Enterprise Value | 123.96M | 193.10M | 271.45M | 140.86M | 425.76M |
| EV to EBITDA | -6.52 | -7.05 | -10.64 | -4.42 | -31.94 |
| EV to Sales | 0.00 | 66.15 | 2714532.53 | 18.75 | 1064395.82 |
| EV to Free Cash Flow | -6.39 | -2.39 | -11.48 | -3.21 | -13.17 |
| EV to Operating Cash Flow | -6.39 | -3.39 | -11.66 | -13.79 | -31.55 |
| Tangible Book Value Per Share | 0.83 | 2.45 | 3.86 | 5.35 | 8.28 |
| Shareholders’ Equity Per Share | 4.27 | 5.12 | 5.99 | 9.01 | 10.12 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.05 | -0.00 |
| Revenue Per Share | 0.00 | 0.14 | 0.00 | 0.54 | 0.00 |
| Net Income Per Share | -0.77 | -1.55 | -1.69 | -0.97 | -0.98 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.38 | 1.00 |
| Interest Burden | 0.71 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.81 | 27185.98 | 1.55 | 6473.51 |
| SG&A to Revenue | 0.00 | 9.27 | 0.00 | 0.80 | 10065.50 |
| Stock-Based Compensation to Revenue | 0.00 | 1.38 | 0.00 | 0.06 | 7087.50 |
| Income Quality | 1.24 | 1.82 | 0.82 | 0.67 | 0.99 |
Currency in PLN
